ADCT Stock Holds $219M Cash at a $144M Valuation

ADC Therapeutics (ADCT) stock analysis: trading below $219M cash — valuation breakdown

👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends

In this deep dive, we break down ADC Therapeutics SA (ADCT) and its high-stakes biopharma turnaround driven by flagship oncology drug ZYNLONTA and upcoming Phase 3 LOTIS-7 clinical trial data. With shares trading at a $144 million market capitalization below its $219.1 million cash balance, the key question for investors is whether LOTIS-7 combination efficacy can overcome recent FDA regulatory friction in LOTIS-5. Here’s everything you need to know before making a decision on ADCT.

🎯 SECTIONS:

- Introduction & ADC Therapeutics Overview

- ZYNLONTA Commercial Performance & Addressable Market

- Q2 Financial Results & $219M Cash Runway Analysis

- FDA LOTIS-5 Regulatory Pause & Impact Breakdown

- LOTIS-7 Catalyst & Expansion into Earlier Indication Lines

- Capital Structure, Debt Obligations & Royalty Liabilities

- 5-Year Bull, Base & Bear Valuation Scenarios

- Final ADCT Stock Verdict & Investment Thesis